Monday, May 3, 2010

Biosante Back on Prostate Cancer Path (BPAX)

Stock Assault 2.0 - Artificial Intelligence Stock Market Software

Biosante Pharmaceuticals, Inc. (NASDAQ: BPAX) is up after announcing that development of its GVAX Prostate Cancer Vaccine has been reinitiated. The company said that manufacturing of the new GVAX Prostate is in process and that regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken.  Further noted was that prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins.

The stock closed at $2.35 on Friday and at 8:44 AM EST we have shares up over 7% at $2.52 on about 73,000 shares.


No comments:

Post a Comment